This 2011 update of Guidelines for the programmatic management of drug-resistant tuberculosis is intended as a tool for use by public health professionals working in response
to the Sixty-second World Health Assembly’s resolution on prevention and control of multidrug-resistant tuberculosis and e...xtensively drug-resistant tuberculosis.
more
HTC COUNTRY REPORT | LESOTHO
Midwifery Capacity Building Strategy for Northern Syria
2017-2021
Available in Arabic
Biennial Report of the Regional Director
Public Health Fact Sheet
Involving the Community in Responding to TB/HIV: Outcomes of Community-Led Monitoring and Advocacy
Accessed November 2017
(Health Systems in Transition, Vol. 4, No. 3, 2014)
The objective of this document is to guide the preparation and implementation of national preparedness plans for the safety of substances of human origin during outbreaks of Zika virus infection, both in affected and non-affected areas.
This catalogue provides tools and information resources to support EU/EEA countries in addressing the challenging issue of vaccine hesitancy. The catalogue provides examples of practices that can serve as a resource for other countries. The project was developed in the context of ECDC’s support fo...r EU/EEA Member States in prevention and control of vaccine-preventable diseases, including effective communication to promote immunisation.
more
The Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020 by the World Health Organization (WHO) outlines a comprehensive strategy to address the global rise in noncommunicable diseases (NCDs), including cardiovascular diseases, cancer, chronic respiratory diseases,... and diabetes.
more
Impact Evalution Report 61
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...ing access to affordable antiretroviral therapy (ART).
The report is supplemented by 11 drug profiles that contain more detailed information on pricing trends and patent barriers for key antiretroviral drugs and fixed-dose combinations. Also included is an annex of conditions that define eligibility for reduced prices from 15 pharmaceutical companies.
more
What We Know, What We Don’t Know, and What We Need to Do